Mak Capital One LLC Invests $10.21 Million in Day One Biopharmaceuticals, Inc. $DAWN

Mak Capital One LLC acquired a new stake in Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 1,448,461 shares of the company’s stock, valued at approximately $10,212,000. Day One Biopharmaceuticals accounts for 1.6% of Mak Capital One LLC’s portfolio, making the stock its 9th biggest holding. Mak Capital One LLC owned about 1.41% of Day One Biopharmaceuticals at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. Rubric Capital Management LP purchased a new stake in Day One Biopharmaceuticals in the 3rd quarter worth approximately $23,808,000. AIGH Capital Management LLC purchased a new position in shares of Day One Biopharmaceuticals during the 3rd quarter valued at $10,719,000. Balyasny Asset Management L.P. purchased a new position in shares of Day One Biopharmaceuticals during the 3rd quarter valued at $9,758,000. Millennium Management LLC increased its holdings in shares of Day One Biopharmaceuticals by 587.2% in the first quarter. Millennium Management LLC now owns 1,320,095 shares of the company’s stock worth $10,468,000 after purchasing an additional 1,127,995 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in shares of Day One Biopharmaceuticals by 232.4% in the first quarter. Goldman Sachs Group Inc. now owns 1,569,918 shares of the company’s stock worth $12,449,000 after purchasing an additional 1,097,679 shares during the period. Hedge funds and other institutional investors own 87.95% of the company’s stock.

Day One Biopharmaceuticals Stock Performance

NASDAQ DAWN opened at $21.36 on Tuesday. Day One Biopharmaceuticals, Inc. has a 52-week low of $5.64 and a 52-week high of $21.43. The company has a fifty day moving average of $12.57 and a 200-day moving average of $9.67. The company has a market capitalization of $2.21 billion, a P/E ratio of -20.74 and a beta of -1.25.

Day One Biopharmaceuticals (NASDAQ:DAWN) last released its earnings results on Tuesday, February 24th. The company reported ($0.21) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.04). Day One Biopharmaceuticals had a negative net margin of 67.85% and a negative return on equity of 23.43%. The firm had revenue of $53.72 million during the quarter, compared to the consensus estimate of $49.81 million. As a group, analysts forecast that Day One Biopharmaceuticals, Inc. will post -0.72 EPS for the current fiscal year.

Insider Activity

In other Day One Biopharmaceuticals news, insider Michael Vasconcelles sold 2,728 shares of the company’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $11.60, for a total value of $31,644.80. Following the completion of the sale, the insider owned 4,397 shares of the company’s stock, valued at $51,005.20. This represents a 38.29% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Adam Dubow sold 6,395 shares of the stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $11.60, for a total transaction of $74,182.00. Following the transaction, the insider owned 72,694 shares in the company, valued at $843,250.40. The trade was a 8.09% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 36,461 shares of company stock worth $422,948. 6.20% of the stock is currently owned by insiders.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on DAWN shares. Oppenheimer reissued a “market perform” rating on shares of Day One Biopharmaceuticals in a research note on Friday, March 6th. Zacks Research lowered Day One Biopharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. HC Wainwright reaffirmed a “neutral” rating and issued a $21.50 price target (down from $22.00) on shares of Day One Biopharmaceuticals in a report on Tuesday, March 10th. JPMorgan Chase & Co. reiterated a “neutral” rating and set a $21.50 price target (down from $27.00) on shares of Day One Biopharmaceuticals in a research report on Wednesday, March 11th. Finally, TD Cowen lowered Day One Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Friday, March 6th. Two equities research analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $23.75.

Day One Biopharmaceuticals Company Profile

Day One Biopharmaceuticals, Inc (NASDAQ: DAWN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for oncology. The company employs a precision medicine approach, leveraging biomarker-driven strategies to identify patient populations most likely to respond to its investigational compounds. By concentrating on well-validated molecular drivers of cancer, Day One seeks to deliver first-in-class or best-in-class therapies with the potential for meaningful clinical benefit.

The company’s pipeline includes several small-molecule candidates in various stages of development.